SAFETY AND EFFICACY OF PROPROTEIN CONVERTASE SUBTILISIN/ KEXIN TYPE 9 INHIBITORS AFTER ACUTE CORONARY SYNDROME; A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

被引：0
|
作者：
Atia, A. [1 ,2 ]
Wageeh, A. [3 ]
Aboeldahab, H. [4 ]
Elneny, M. [5 ]
Abdelwahab, M. [6 ]
Elmallahy, M.
Aboelkhier, M. [7 ,8 ]
Elawfi, B. [9 ]
Sayed, S. [10 ]
Elrosasy, A. [1 ]
机构：
[1] Cairo Univ, Cardiol, Fac Med, Cairo, Egypt
[2] Med Res Grp Egypt, Cardiol, Cairo, Egypt
[3] Menoufia Univ, Cardiol, Fac Med, Menoufia, Egypt
[4] Alexandria Univ, Med Res Inst, Biomed Informat & Med Stat Dept, Biomed Informat & Med Stat, Alexandria, Egypt
[5] Al Azhar Univ, Damietta Fac Med, Cardiol, Dumyat, Egypt
[6] Helwan Univ, Cardiol, Fac Med, Cairo, Egypt
[7] Tanta Univ, Cardiol, Fac Med, Tanta, Egypt
[8] Suez Canal Univ, Master Program, Sci, Fac Sci, Ismailia, Egypt
[9] Sanaa Univ, Cardiol, Fac Med, Sanaa, Yemen
[10] Minia Univ, Cardiol, Fac Med, Al Minya, Egypt
来源：
ATHEROSCLEROSIS | 2023年 / 379卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P248
引用
收藏
页码：S78 / S80
页数：2
相关论文
共 50 条
  • [1] Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials
    Atia, Ahmed
    Aboeldahab, Heba
    Wageeh, Ahmed
    Elneny, Mohamed
    Elmallahy, Mohamed
    Elawfi, Bashaer
    Aboelkhier, Menna M.
    Elrosasy, Amr
    Abdelwahab, Maya Magdy
    Sayed, Somaya
    Abdelaziz, Ahmed
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2024, 24 (01) : 83 - 102
  • [2] Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials
    Ahmed Atia
    Heba Aboeldahab
    Ahmed Wageeh
    Mohamed Elneny
    Mohamed Elmallahy
    Bashaer Elawfi
    Menna M. Aboelkhier
    Amr Elrosasy
    Maya Magdy Abdelwahab
    Somaya Sayed
    Ahmed Abdelaziz
    American Journal of Cardiovascular Drugs, 2024, 24 : 83 - 102
  • [3] Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and the Risk of Fracture: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Lv, Fang
    Cai, Xiaoling
    Lin, Chu
    Yang, Wenjia
    Hu, Suiyuan
    Ji, Linong
    CALCIFIED TISSUE INTERNATIONAL, 2023, 113 (02) : 175 - 185
  • [4] Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary syndrome: A systematic review and meta-analysis
    Song, Ruohong
    Li, Jinsong
    Xiong, Yan
    Huang, Hui
    Liu, Xiaojian
    Li, Qiyong
    MEDICINE, 2024, 103 (22) : E38360
  • [5] Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and the Risk of Fracture: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Fang Lv
    Xiaoling Cai
    Chu Lin
    Wenjia Yang
    Suiyuan Hu
    Linong Ji
    Calcified Tissue International, 2023, 113 : 175 - 185
  • [6] Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis
    Li, Jing
    Du, Heyue
    Wang, Yang
    Aertgeerts, Bert
    Guyatt, Gordon
    Hao, Qiukui
    Shen, Yanjiao
    Li, Ling
    Su, Na
    Delvaux, Nicolas
    Bekkering, Geertruida
    Khan, Safi U.
    Riaz, Irbaz B.
    Vandvik, Per Olav
    Su, Baihai
    Tian, Haoming
    Li, Sheyu
    HEART, 2022, 108 (16) : 1296 - 1302
  • [7] Efficacy and safety of proprotein covertase subtilisin/kexin type 9 inhibitors among patients with acute coronary syndrome: a meta-analysis of randomized controlled trials
    Delgado, S.
    Tiongco, R. H.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1399 - 1399
  • [8] Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis
    Nagendra, Lakshmi
    Mahajan, Kunal
    Gupta, Gunjan
    Dutta, Deep
    INDIAN HEART JOURNAL, 2023, 75 (06) : 416 - 422
  • [9] Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Chen, Qiwen
    Wu, Guodong
    Li, Chuang
    Qin, Xueting
    Liu, Rui
    Zhang, Mei
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (04) : 343 - 353
  • [10] Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Qiwen Chen
    Guodong Wu
    Chuang Li
    Xueting Qin
    Rui Liu
    Mei Zhang
    American Journal of Cardiovascular Drugs, 2020, 20 : 343 - 353
12345